JP2012509886A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509886A5
JP2012509886A5 JP2011537606A JP2011537606A JP2012509886A5 JP 2012509886 A5 JP2012509886 A5 JP 2012509886A5 JP 2011537606 A JP2011537606 A JP 2011537606A JP 2011537606 A JP2011537606 A JP 2011537606A JP 2012509886 A5 JP2012509886 A5 JP 2012509886A5
Authority
JP
Japan
Prior art keywords
tcl1
activator protein
promotes
pharmaceutical composition
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/065072 external-priority patent/WO2010059779A1/en
Publication of JP2012509886A publication Critical patent/JP2012509886A/ja
Publication of JP2012509886A5 publication Critical patent/JP2012509886A5/ja
Pending legal-status Critical Current

Links

JP2011537606A 2008-11-21 2009-11-19 転写制御因子としてのＴｃｌ１ Pending JP2012509886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11678608P 2008-11-21 2008-11-21
US61/116,786 2008-11-21
PCT/US2009/065072 WO2010059779A1 (en) 2008-11-21 2009-11-19 Tcl1 AS A TRANSCRIPTIONAL REGULATOR

Publications (2)

Publication Number Publication Date
JP2012509886A JP2012509886A (ja) 2012-04-26
JP2012509886A5 true JP2012509886A5 (enExample) 2012-06-07

Family

ID=42198493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537606A Pending JP2012509886A (ja) 2008-11-21 2009-11-19 転写制御因子としてのＴｃｌ１

Country Status (7)

Country Link
US (1) US20110311555A1 (enExample)
EP (1) EP2352524A1 (enExample)
JP (1) JP2012509886A (enExample)
CN (1) CN102271706A (enExample)
AU (1) AU2009316584A1 (enExample)
CA (1) CA2744326A1 (enExample)
WO (1) WO2010059779A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103820562B (zh) 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP2009507918A (ja) 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
ES2553442T3 (es) 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
EP2041317A4 (en) 2006-07-13 2009-10-14 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
EP2061907B1 (en) 2006-09-19 2011-11-23 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
ES2537349T3 (es) 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
EP2307028B1 (en) 2008-06-11 2013-10-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US20010026796A1 (en) * 2000-03-14 2001-10-04 Croce Carlo M. TCL1 enhances Akt kinase activity and mediates its nuclear translocation
GB0128898D0 (en) * 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
CN1653059A (zh) * 2002-03-08 2005-08-10 卫材株式会社 用作医药品的大环化合物

Similar Documents

Publication Publication Date Title
JP2012509886A5 (enExample)
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
WO2006122257A3 (en) Nebulization of monoclonal antibodies for treating pulmonary diseases
HK1210792A1 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
UA113712C2 (xx) Антитіло до fap і способи його застосування
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
JP2007051159A5 (enExample)
IL219653A0 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
MX2012012927A (es) Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
BR112012013876A2 (pt) proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos
JP2006506333A5 (enExample)
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
JP2007520566A5 (enExample)
NZ606880A (en) Antibodies to matrix metalloproteinase 9
EA202192294A1 (ru) Антитела к trem2 и способы их применения
EA201400488A1 (ru) Полипептидные конструкции и их применение
GEP20135930B (en) ANTI-cMET ANTIBODY
HUE060029T2 (hu) Emberi antitestek, amelyek kötnek limfocita aktivációs gént-3 (LAG-3) és azok felhasználásai
JP2015500002A5 (enExample)
WO2010005566A3 (en) Notch-binding agents and antagonists and methods of use thereof
IL226957B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
WO2020065330A3 (en) Chimeric antigen receptor
JP2008535821A5 (enExample)
EA200901421A1 (ru) Антитела к il-25